SHST Medical Technology Group focuses on the R&D and industrialization of implant/interventional devices for minimally invasive surgery to treat cerebrovascular diseases. SHST ushered in a new era of domestic neurointerventional devices. The company developed and industrialized China's first cerebrovascular stent for neurological intervention, China's first intracranial artery stenosis stent, the world's first intracranial stent graft, and China's first blood flow guiding device. The product has entered more than 1,000 hospitals across the country and treated 70,000 patients.
SHST broke the monopoly of foreign products, promoted the innovation and industrialization of domestic neurointerventional products, created a high-end domestic medical device brand for patients and doctors, and reduced surgical costs for Chinese patients by 20%-50%.
Case Introduction
In 2005, SHST worked closely with the team of Professor Liu Jianmin from Changhai Hospital to start the research and development of the first domestic vascular reconstruction device, determined to develop a world-leading dense mesh stent product to solve traditional coil embolization or stent-assisted coil embolization treatment The problem of high cost and high recurrence after treatment.
Changhai Hospital started from clinical needs, and SHST realized from engineering technology, and finally developed a cerebrovascular stent-vascular reconstruction device that is not only suitable for ordinary aneurysms, but also can solve the problem of large and huge wide-necked aneurysms. The product is in the pre-market clinical project, led by Changhai Hospital, and cooperated with 12 top cerebrovascular centers in China. It took 5 years to complete a prospective, multi-center, randomized controlled study. It is the first blood flow guiding device in the world. RCT study for the treatment of large and giant aneurysms.
After such a high-standard and high-demand clinical project, the cerebrovascular stent-vascular reconstruction device became the first neurointervention product approved to enter the cfda innovative medical device special approval process (green channel), and it is also the only domestic blood flow guidance equipment. . This product was certified for the market in March 2018, and developed the endovascular treatment of intracranial aneurysms from "intracranial aneurysm packing" to "aneurysm-bearing artery revascularization", marking a fundamental of the concept and method of aneurysm intervention change. It has occupied 40% of the domestic market share after only two years of listing, ranking second in market share.
Products
Coil embolization system
The coil embolization system is used for the embolization of intracranial aneurysms. It can fill the aneurysm with embolisms such as micro coils through a minimally invasive approach to block the aneurysm and avoid the risk of craniotomy.
Vascular reconstruction device
The research and development and design for large and giant intracranial aneurysms have realized a fundamental change in the treatment of intracranial aneurysms from the traditional "aneurysm sac embolization" to the new concept and method of "vascular reconstruction of the aneurysmal artery".
Intracranial stent graft system
The stent graft product used to treat intracranial aneurysms can completely block the aneurysm.
Intracranial artery stent system
It is suitable for the treatment of lesions such as intracranial artery stenosis or obstruction, and is used to improve cerebral ischemia.
Vertebral artery rapamycin targeting eluting stent system
It is suitable for the treatment of symptomatic vertebral artery extracranial stenosis.
Intracranial support catheter system
Microcatheter system
Nine-level gradient, full of power
Neurovascular guide wire
Neurovascular guide wire can provide excellent twist control feedback, strong support and head end durability